Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382096 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,179
- Enrollment target
NCT00382096: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00382096 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,179 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382096, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,179 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes
Interventions
- DRUG Metformin
- DRUG Vildagliptin
- DRUG Vildagliptin + Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,179 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-06-03 |
| Phase | Phase 3 |
What the finished NCT00382096 record still lists
NCT00382096 is an interventional study that assigns participants to a tested intervention. Its 1,179 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00382096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00382096 about?
NCT00382096 is a clinical study titled "Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes
What is the current status of trial NCT00382096?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,179 participants. The study started on 2006-09. Estimated completion is 2008-06-03.
What interventions are being tested in trial NCT00382096?
The interventions under investigation include: Metformin (DRUG), Vildagliptin (DRUG), Vildagliptin + Metformin (DRUG).
Who is sponsoring clinical trial NCT00382096?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00382096's enrollment target sits among peer trials
1,179 235th of 2000 higher than 1,766 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia